Cure My Disease

Don't miss your cure!

 Log in / Sign up

A clogged artery behind dry macular degeneration? a new scan puts it to the test

NCT ID NCT07798323

Knowledge-focused Sponsor: Scott Raymond Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

Researchers are investigating whether narrowing of the ophthalmic artery, which supplies blood to the eye, contributes to geographic atrophy, an advanced form of dry age-related macular degeneration. The study will use a noninvasive imaging technique called PC-CTA to measure artery narrowing in 30 adults aged 50 to 80 with asymmetric dry AMD. The goal is to see if this narrowing correlates with disease severity and progression, which could reveal a treatable vascular factor in this vision-threatening condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Noninvasive imaging (PC-CTA) to measure ophthalmic artery stenosis
What this could lead to
If a link is found, it could point to a treatable vascular cause for dry AMD progression, opening new avenues for therapy.
What could go wrong
This is a small observational study, so it may not prove cause and effect. Imaging quality or variability could limit results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective study will enroll 30 patients from 50-80 years of age with geographic atrophy in one eye and mild to moderate AMD in the fellow eye according to International Classification of Disease (ICD) codes treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 50-80 years of age * All genders * Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes * Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio Exclusion Criteria: * Poor image quality that limits quantification * GA extending beyond the borders of the SDOCT field of view. * Bilateral symmetric geographic atrophy. * Diagnosis of wet AMD. * Any retinal fluid at baseline. * Other concurrent retinal diseases * Vitreoretinal surgery. * Allergy to iodinated contrast agents. * Chronic kidney disease with eGFR \< 60

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry age-related macular degeneration with geographic atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.